A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction

Pharmacotherapy

Volumn 21, Issue 2, 2001, Pages 207-217

  Tsikouris, James P ^a   Tsikouris, Alexander P ^b  

^a TEXAS TECH UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ANTIPLASMIN; ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR; RETEPLASE; STREPTOKINASE; TENECTEPLASE; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANIMAL MODEL; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

BLOOD COAGULATION; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; SURVIVAL RATE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0035146406     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.2.207.34103     Document Type: Review

References (44)

1. Treatment of myocardial infarction in the United States: Observations from the National Registry of Myocardial infarction
2. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
3. A comparison of reteplase with alteplase for acute myocardial infarction
4. The wavefront phenomenon of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow
5. Coronary thrombosis: Pathogenesis and clinical manifestations
6. Risk of thrombosis in human atherosclerotic plaques: Rote of extracellular lipid, macrophage, and smooth muscle cell content
7. Coronary plaque disruption
8. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
9. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction
10. Serial thrombolysis-related changes after thrombolytic therapy with tPA in patients with acute myocardial infarction
11. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10A doseranging trial
12. TNK-tissue plasminogen activator compared with front loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
13. Effect of reteplase on hemostasis variables: Analysis of fibrin specificity, relation to the bleeding complications and coronary patency
14. Comparative thrombolytic properties of tissue-type plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog
15. A faster-acting more potent form of tissue plasminogen activator
16. A long half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding
17. Serpin resistant mutants of human tissue-type plasminogen activator
18. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction
19. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction
20. Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator
21. Reteplase: A review of its pharmacologic properties and clinical efficacy in the management of acute myocardial infarction
22. Tissue-type plasminogen activator: A review of its pharmacology and therapeutic use as a thrombolytic agent
23. Thrombolytic agents
24. Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients wish acute anterior wall myocardial infarction
25. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian study of early thrombolysis (ASSET)
26. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study
27. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
28. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
29. Use of reperfusion therapy for acute myocardial infarction in the United States: Data from the National Registry of Myocardial Infarction 2
30. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings
31. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction
32. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
33. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
34. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
35. Randomized, double blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction
36. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial
37. Task Force on Practice Guidelines. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations
38. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
39. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial